

Insulin/Injectable Combos

PocketCards are updated twice yearly.
Scan QR code to download or
order the latest version.



Name	Combines	Considerations
IDegLira* Xultophy 100/3.6	Insulin degludec (IDeg or Tresiba) Ultra long insulin + Liraglutide (Victoza) GLP-1 Receptor Agonist (GLP-1 RA)	Xultophy 100/3.6 pre-filled pen = 100 units IDeg / 3.6 mg liraglutide per mL Once daily injection – Dose range 10 to 50 = 10 – 50 units IDeg + 0.36 -1.8 mg liraglutide Recommended starting dose: • 16 IDegLira (= 16 units IDeg + 0.58 mg liraglutide) Titrate dose up or down by 2 units every 3-4 days to reach target. Supplied in package of five single-use 3mL pens. Once opened, good for 21 days.
iGlarLixi* Soliqua 100/33	Insulin glargine (Lantus) Basal Insulin + Lixisenatide (Adlyxin) GLP-1 Receptor Agonist	Soliqua 100/33 Solostar Pen = 100 units glargine / 33 µg lixisenatide per mL Once daily injection an hour prior to first meal of day. Dose range 15 – 60 = 15-60 units glargine + 5 – 20µg lixisenatide Recommended starting dose: • 15 units if not meeting glucose target on 30 units basal insulin or GLP-1 RA • 30 units if not meeting glucose target on 30-60 units basal insulin or GLP-1 RA Titrate dose up or down by 2-4 units every week to reach target. Supplied in package of five single-use 3mL pens. Once opened, good for 14 days.

***Discontinue basal insulin /GLP-1 RA therapy before starting. If dose missed, resume with next usual scheduled dose.**

Observe precautions of each component drug.

GLP-1 & GIP Receptor Agonists

Class/Main Action	Name	Dose Range	Considerations
GLP-1 RA - Glucagon Like Peptide Receptor Agonist "Incretin Mimetic" - Increases insulin release with food - Slows gastric emptying - Promotes satiety - Suppresses glucagon	exenatide (Byetta)	5 and 10 mcg BID	Side effects: nausea, vomiting, weight loss, injection site reaction. Report signs of acute pancreatitis or intestinal blockage (ileus) and stop med. Black box warning: Thyroid C-cell tumor warning (avoid if family history of medullary thyroid tumor). *Significantly reduces risk of CV death, heart attack, and stroke. §Approved to reduce risk of CKD †Approved for pediatrics 10-17 yrs Lowers A1C 0.5 – 1.6% Weight loss: 4-6% body weight loss.
	exenatide XR [†] (Bydureon)	2 mg 1x a week Pen injector - Bydureon BCise	
	liraglutide* [†] (Victoza)	0.6, 1.2 and 1.8 mg daily	
	dulaglutide* [†] (Trulicity)	0.75, 1.5, 3.0 and 4.5 mg 1x a week pen injector	
	semaglutide* [§] (Ozempic) (Rybelsus) Oral tablet	0.25, 0.5, 1.0 and 2.0 mg 1x a week pen injector 3, 7, 14 mg - Original dosing. 1.5, 4, 9 mg - New dosing. AM dose, pre-food, w/ water sip	
GLP-1 & GIP Receptor Agonist Activates receptors for GLP-1 (see above) & Glucose-dependent Insulinotropic Polypeptide (GIP).	Tirzepatide (Mounjaro)	2.5, 5.0, 7.5, 10, 12.5 and 15 mg 1x a week injection Single dose via prefilled pen or vial. Adjust dose based on shared decision making and individual goals.	Side effects: nausea, diarrhea, injection site reaction. Report pancreatitis, signs of intestinal blockage. Black box warning: Avoid if family history of medullary thyroid tumor. Lowers A1C ~ 1.8 - 2.4% Weight loss: 7-13% body weight loss at max dose.